Multiple Myeloma Articles

FDA Lifts Partial Clinical Hold on Venetoclax Myeloma Trial
The FDA has lifted a partial clinical hold that was placed on the phase III CANOVA (M13-494; NCT03539744) trial, which is examining venetoclax in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma that harbors t(11;14), according to AbbVie, the company that co-develops the BCL-2 inhibitor with Roche.
Rapid Changes in Multiple Myeloma Provide a Windfall of Treatment Options
S. Vincent Rajkumar, MD, discusses the rapidly changing landscape for the treatment of multiple myeloma, the future of immunomodulatory drugs, and whether quadruplet regimens will become more frequent.
Phase III BELLINI Data Showcase Safety Concerns With Venetoclax in Multiple Myeloma
Despite promising progression-free survival and response data with venetoclax in combination with bortezomib and dexamethasone, an increased number of deaths due to infection in the experimental arm marred overall survival findings in patients with relapsed/refractory multiple myeloma.
Elotuzumab Triplet Continues to Show Survival Benefit in Relapsed/Refractory Myeloma
The triplet regimen of elotuzumab plus pomalidomide and dexamethasone led to a 46% reduction in the risk of death compared with pomalidomide/dexamethasone alone in patients with relapsed/refractory multiple myeloma, according to updated findings of the phase II ELOQUENT-3 trial. 
Innovation Fuels Survival Gains in Multiple Myeloma
While the expansion of therapeutic opportunity in multiple myeloma has been incremental in some ways, it’s been continuous and, when seen in aggregate, the impact is considerable.
Yubin Kang, MD, discusses how progress made in frontline therapy has impacted the outlook of multiple myeloma and the remaining work that needs to be done across settings.
Isatuximab Triplet Significantly Improves PFS in Myeloma
Adding isatuximab to pomalidomide and low-dose dexamethasone led to a greater than 40% reduction in the risk of disease progression or death compared with pomalidomide and dexamethasone alone in patients with relapsed/refractory multiple myeloma.
Subcutaneous Daratumumab Shows Similar Efficacy, Greater Convenience in Phase III Myeloma Trial
A subcutaneous flat-dose version of daratumumab demonstrated noninferior efficacy with a reduction in the treatment burden compared with the original intravenous formulation of the anti-CD38 monoclonal antibody for patients with relapsed/refractory multiple myeloma.
Alarm Sounded Over Multiple Myeloma Outcomes Versus Socioeconomics
Higher income was associated with significantly greater probability of survival for patients with multiple myeloma, according to authors of a study they performed to call attention to the need to address socioeconomic disparities that influence treatment outcomes.
FDA Grants Frontline Daratumumab Regimen Priority Review in Transplant-Eligible Myeloma
The FDA has granted a priority review designation to a supplemental biologics license application for daratumumab in combination with bortezomib, thalidomide, and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.
Publication Bottom Border
Border Publication